What question did this study set out to answer?

The study aims to evaluate the benefits of BTK inhibitor-based therapy in patients experiencing histologic transformation of Waldenström macroglobulinemia to DLBCL.

March 12, 2026Open Access

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia

Key Points

The study aims to evaluate the benefits of BTK inhibitor-based therapy in patients experiencing histologic transformation of Waldenström macroglobulinemia to DLBCL.
Retrospective analysis of patient records at a single center
Examination of treatment regimens using BTK inhibitors
Assessment of survival outcomes in transformed patients
Patients receiving BTK inhibitor-based therapy exhibited improved survival rates
Histologic transformation to DLBCL showed aggressive behavior and poorer prognosis without treatment
Frequent extranodal involvement was noted in transformed cases

Abstract

Although rare, histologic transformation from WM to DLBCL exhibits aggressive clinical behavior, frequent extranodal involvement, and poor prognosis. BTKi-based regimens may provide significant survival benefits in this patient population.

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia

Key Points

Abstract

Cite This Study